-
Eltrombopag Drugs Market CAGR to be at 8.7% from 2025 to 2029 | $3.47 Billion Industry Revenue by 2029
11 Sep 2025 00:15 GMT
… medical professionals, an increasing inclination for orally administered alternatives over injectable remedies … Clinical Trials for New and Effective Treatment Options … Novartis AG
• GlaxoSmithKline plc
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd
• …
-
With FDA nod, Sanofi's Wayrilz becomes 1st US BTK drug approved for immune thrombocytopenia
30 Aug 2025 03:48 GMT
… the biotech has made it across the FDA finish line first.
The drug … specifically benefit from the new medication in the U.S.
… Amgen’s Nplate or Novartis’ Promacta. Roche’s Rituxan is also … with Principia as a potential treatment for multiple sclerosis (MS).
…
-
Eltrombopag Drugs Market Size Projected to Drive USD 5.28 Billion by 2034
19 Aug 2025 14:00 GMT
… .
Precision Medicine and Personalized … treatment. Novartis reported notable sales of Promacta … global cancer drug manufacturing market … Drugs Market Key Players
Ningbo Menovo Tiankang Pharmaceutical
Longfu Pharmaceutical
Guangdong
Shandong Jewim Pharmaceutical …
-
Impact of Primary Chronic Immune Thrombocytopenia and Thrombopoietin Receptor Agonists Treatment Instructions on Daily Living: Results of a Multinational Cross-Sectional Survey
12 Aug 2025 21:08 GMT
… Amgen), eltrombopag (Revolade®/Promacta®, Novartis) and avatrombopag (Doptelet … about treatment was most commonly received via a doctor ( … analysis of randomized controlled trial. Front Pharmacol. … Drugs and Medical Devices. DRKS - German Clinical Trials …
-
Immune Thrombocytopenic Purpura Market to Grow at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight
15 Sep 2025 17:00 GMT
… purpura medications are … Drug Administration (FDA) has approved DOPTELET (avatrombopag) for the treatment … Pharmaceutical), Pfizer, Genosco, Oscotec, Rigel Pharmaceuticals, Kissei Pharmaceutical, Grifols, Sobi (Dova Pharmaceuticals …
10.5
PROMACTA/REVOLADE …
-
Medicare Cuts to Critical Cancer Care Leave Civil Rights Icon Charles D. Neblett, PhD, Denied Coverage
07 Jul 2025 20:18 GMT
… still denied the critical cancer medication his doctors prescribed.
The 84-year … cancer, received approval for Promacta™, a critical platelet-stabilizing medication. But the drug … low platelet counts during prostate cancer treatment—and if your platelets …
-
Civil Rights Icon Charles D. Neblett, PhD, Denied Critical Cancer Care Coverage Despite July 1 Medicare Policy Change
02 Jul 2025 19:08 GMT
Denied Cancer Treatment Coverage Despite New Medicare Policy, Civil Rights Icon Inspires … coordination with legacy leaders, journalists, doctors, and grassroots organizers.
“My work … the Black Prostate Check Challenge™. Promacta™ is a trademark of Novartis …
-
Civil Rights Icon Charles D. Neblett, PhD, Denied Critical Cancer Care Coverage Despite July 1 Medicare Policy Change
02 Jul 2025 23:51 GMT
Denied Cancer Treatment Coverage Despite New Medicare Policy, Civil Rights Icon Inspires … months, Neblett has gone without Promacta™, and his platelet count has … coordination with legacy leaders, journalists, doctors, and grassroots organizers.
“My work …
-
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
24 Jun 2025 11:05 GMT
… cancer
-
Draw
Required
Required
Revolution Medicines option
Revolution Medicines option
Revolution Medicines … 2.40%
FDA: Food and Drug Administration; 1L … biotechnology companies to leading global pharmaceutical companies … Xtandi, Novartis’ Promacta, Pfizer’s …
-
Aplastic Anemia Treatment Market Size In The 7MM Was ~USD 270 Million In 2023 And Is Further Expected To Increase By 2034, Estimates Delveinsight
12 Jun 2025 00:12 GMT
… Cancer Center organized phase II trial … patient uptake of PROMACTA (until expected … Trials Assessment
Aplastic Anemia Companies
Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals … FDA-approved drugs for Aplastic Anemia @ Drugs for Aplastic Anemia Treatment …
About
© 1995-2025